A recent study (Inflamm Bowel Dis 2015; 21: 1047-53) explored the “Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn’s Disease.”
Methods: Between 2011-2012, 42 adults with active Crohn’s disease, defined by CDAI > 150 and an objective marker of inflammation, had a dose escalation of adalimumab to 80 mg weekly in prospective multi center study.
- Objective markers could include CRP >0.5 mg/dL, fecal calprotectin >300 mcg/g, radiologic evidence or endoscopic evidence
- Only 4 patients were receiving concomitant immunomodulators (& none were started)
- There were no reports of adalimumab drug levels
Findings: At 14 weeks, 33.3% achieved a clinical remission (CDAI <150) and 23 (54.8%) had a clinical response. These patients had associated improvements in CRP. The authors do not report on serious adverse events; all AEs “were consistent with previous experience with this drug.”
Take-home point: The authors do not recommend this approach in routine clinical practice at this time. However, it would seem that some patients with low adalimumab trough levels (and no anti-drug antibodies) may benefit from high doses of adalimumab
Fumery M, et al. JPGN 2015; 60: 744-48. This retrospective study identified 27 children who received adalimumab (ADA) after infliximab failure. Though ADA was well-tolerated, 8 (30%) had primary nonresponse to ADA and an additional 5 (26%) had ADA failure by 1 year.
Huang EY, et al. Inflamm Bowel Dis 2015; 21: 963-72. “Exposure to dexamethasone in mice led to substantial shifts in gut microbiota over a 4-week period.” Take-home point: Corticosteroids may have both direct and indirect impacts on the microbiome as one mechanism of influencing disease response
Related blog posts:
- Adalimumab for children with Crohn’s disease | gutsandgrowth
- More on Adalimumab (Humira) in Pediatrics | gutsandgrowth
- What We Know Now: Therapeutic Drug Monitoring for …
- More NASPGHAN Meeting Notes: IBD Hot Topics | gutsandgrowth